Clinical trials: Hypertrophic Cardiomyopathies
Hypertrophic Cardiomyopathy
Non-Invasive Radiation Ablation in Patients With Hypertrophic CardioMyopathy: NIRA-HOCM
Hypertrophic cardiomyopathy (HCM) is a common disease of the heart which causes thickening of the heart muscle. HCM primarily affects the muscle of the main pumping chamber of the heart (the left ventricle) and particularly the…
- Trial name
- NIRA-HOCM (NCT04153162)
- Testing
- Stereotactic body radiation therapy
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Barts & The London NHS Trust
Coronary Artery Disease, Heart Failure
Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD.
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Congenital Heart Disease
- Trial name
- SE2030 (NCT05081115)
- Testing
- ABCDE-Stress Echo, SE diastolic assessment, SE Right ventricular function assessment
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Fatebenefratelli Hospital
Hypertrophic Cardiomyopathy With Obstruction
Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY
This investigation is a prospective, randomized, single-blinded and multicenter design. The purpose of this study is to evaluate the benefit of atrial-synchronous biventricular (BiV) pacing in severely symptomatic hypertrophic…
- Trial name
- TRICHAMPION (NCT01614717)
- Testing
- CRT-P Implant
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Abbott Medical Devices
Hypertrophic Cardiomyopathy
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
The overall aim of this project is to establish potential benefits of a novel lifestyle (physical activity and dietary nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor) interventions in patients with…
- Trial name
- SILICOFCM (NCT05366101)
- Testing
- Sacubitril/Valsartan, Lifestyle
- Where
- United Kingdom
- Volunteers
- 168 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Hypertrophic Cardiomyopathy
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy
Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.
- Trial name
- PRIMARy (NCT02994615)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hypertrophic Obstructive Cardiomyopathy, Stereotactic Body Radiotherapy
Safety and Efficacy of Stereotactic Body Radiotherapy in the Treatment of Hypertrophic Obstructive Cardiomyopathy
This study is designed to rigorously evaluate the safety and effectiveness of Stereotactic Body Radiotherapy (SBRT) as an innovative, non-invasive treatment for Hypertrophic Obstructive Cardiomyopathy (HOCM).
- Trial name
- SAFECARE (NCT06167876)
- Testing
- Stereotactic Body Radiotherapy (SBRT) Treatment
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Second Xiangya Hospital of Central South University
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia
Extended ECG Monitoring in HCM Patients
The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc.
- Conditions
- Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation
- Trial name
- EXAMINE-HCM (NCT04056715)
- Testing
- Zio XT
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- iRhythm Technologies, Inc.
Obstructive Hypertrophic Cardiomyopathy
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac…
- Trial name
- NCT06116968
- Testing
- Aficamten
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Corxel Pharmaceuticals